Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
An announcement from Sutro Biopharma ( (STRO) ) is now available.
On August 12, 2026, Sutro Biopharma reported second quarter 2026 financial results and released new clinical data from its Phase 1 STRIVE-01 study of STRO-004, a Tissue Factor-targeting DAR8 exatecan ADC in heavily pretreated patients with advanced solid tumors. The U.S.-only trial, which began in November 2025, showed multiple partial responses across pancreatic, head and neck, and non-small cell lung cancers, alongside a favorable tolerability profile and predictable pharmacokinetics that allow dosing at the high end of the class.
Dose escalation from 1 to 5 mg/kg enrolled 49 patients faster than expected, with dose-limiting toxicities only at the highest dose and a low adverse event-related discontinuation rate of 6 percent, underscoring the potential for wider therapeutic index and combination use of STRO-004. Sutro highlighted comparable preclinical PK profiles for STRO-006 and STRO-227, with STRO-006 set to enter Phase 1 in the third quarter of 2026 and STRO-227 on track for an IND filing in 2026, signaling rapid pipeline expansion in next-generation single- and dual-payload ADCs.
The company also reported continued progress under its Astellas collaboration on dual-payload immunostimulatory ADCs, including an active TROP2-targeting program that triggered a $10 million milestone payment in April 2026 and a second program expected to reach the clinic by year-end 2026. Financially, Sutro closed June 30, 2026 with $164.3 million in cash, cash equivalents and marketable securities, down from $202.6 million at March 31, 2026, with quarterly revenue of $9.8 million primarily from Astellas and reduced combined R&D and G&A expenses versus the prior-year quarter, supporting operations into at least the second quarter of 2028.
The most recent analyst rating on (STRO) stock is a Buy
with a $48.00 price target.
To see the full list of analyst forecasts on Sutro Biopharma stock,
see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.
STRO scores low primarily due to weak financial performance—large ongoing losses, heavy cash burn, negative equity, and a sharply contracting/volatile revenue profile. Technicals add downside pressure with a bearish trend across key moving averages and negative MACD (despite oversold readings). Valuation provides limited support because the negative P/E reflects loss-making operations and there is no dividend yield data.
To see Spark’s full report on STRO stock,
click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on oncology, pioneering a next-generation antibody-drug conjugate platform that produces single- and dual-payload ADCs using a cell-free manufacturing approach. Its pipeline targets large cancer markets with limited treatment options, aiming to improve drug exposure, reduce side effects and overcome treatment resistance through novel ADC formats and dual-payload designs.
The company’s proprietary technology is designed to optimize antibodies, linkers and payloads to widen the therapeutic index and expand the range of treatable tumor types. Sutro also collaborates with partners such as Astellas on immunostimulatory ADC programs, reinforcing its positioning as a specialist in advanced ADC engineering for solid tumors with high unmet need.
Average Trading Volume: 343,082
Technical Sentiment Signal: Buy
Current Market Cap: $423M
For detailed information about STRO stock, go to TipRanks’ Stock Analysis page.